Company Overview
Company Type: Public Company
Website: www.abetterlifepharma.com
Number of Employees: 7
Ticker: BETR.F (OTCPK)
Year Founded: 2002


Business Description
BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company’s products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
8.1
EBITDA
(6.8)
Total Enterprise Value
10.8
TEV/EBITDA
NM
EBIT
(6.8)
Cash & ST Invst.
0.1
P/Diluted EPS Before Extra
NM
Net Income
(6.7)
Total Debt
0.1
Price/Tang BV
NM
Total Assets
0.4
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jul-31-2023 TEV and Market Cap are calculated using a close price as of Oct-03-2023

Key Professionals
Name
Title
Doroudian, Ahmad 
Founder, CEO & Chairman
Ong, Moira 
Chief Financial Officer
Sheshbaradaran, Hooshmand 
Chief Operating Officer
Calandra, Anthony 
Head of Regulatory
Ghaffari, Abdi 
Head of Preclinical & Toxicology
Rudge, Scott 
Head of CMC

Key Board Members
Name
Title
Doroudian, Ahmad 
Founder, CEO & Chairman
Aguilar-Valles, Argel 
Member of Scientific Advisory Board
Halberstadt, Adam 
Member of Scientific Advisory Board
McCorvy, John D.
Member of Scientific Advisory Board
Metcalfe, Robert James
Independent Director
Pullen, Ralph Anthony
Independent Director
Renz, Wolfgang 
Independent Director
Swaim, Mark 
Member of Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
1275 West 6th Avenue Suit 300 | Vancouver, BC | V6H 1A6 | Canada
Phone: 604-221-0595   Fax: 604-738-7134

Current and Pending Investors
Negev Capital

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.07
Market Cap (mm)
8.1
Open
 0.07
Shares Out. (mm)
113.8
Previous Close
 0.07
Float %
90.1%
Change on Day
0.0010
Shares Sold Short (mm)
0.0
Change % on Day
1.5%
Dividend Yield %
-
Day High/Low
 0.07/ 0.07
Diluted EPS Excl. Extra Items
(0.07)
52 wk High/Low
 0.21/ 0.04
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0053
Avg 3M Dly Vlm (mm)
0.03
Beta 5Y
1.42


 
Delayed Quote** | Last Updated on Oct-03-2023 12:00 AM (GMT-5)
OTCPK:BETR.F - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Assets of Transcend Biodynamics LLC
As of December 18, 2020, Assets of Transcend Biodynamics LLC was acquired by BetterLife Pharma Inc.

United States and Canada
-
-
-
-
Blife Therapeutics Inc.
Blife Therapeutics Inc. engages in the prevention of severe COVID-19 disease. Blife Therapeutics Inc. was formerly known as Opes Pharmaceuticals Inc. and changed its name to Blife Therapeutics Inc. in May 2020. The company was incorporated in 2015 and is based in Vancouver, Canada. As of May 7, 2020, Blife Therapeutics Inc. operates as a subsidiary of BetterLife Pharma Inc.

United States and Canada
Pharmaceuticals
-
-
-
Altum Pharmaceuticals Inc.
Altum Pharmaceuticals Inc. operates as a biopharmaceutical company that develops clinical and commercial healthcare products. The company is developing AP-001, for Cervical Dysplasia/Cancer and Human Papilloma Virus (HPV); AP-002, for Solid Tumors with Bone Metastases or at Risk of Bone Metastases; and AP-003, for COVID-19. Altum Pharmaceuticals Inc. was founded in 2016 and is based in Vancouver, Canada. As of August 31, 2020, Altum Pharmaceuticals Inc. operates as a subsidiary of BetterLife Pharma Inc.

United States and Canada
Life Sciences Tools and Services
-
-
-
Altum Pharmaceuticals Inc., Worldwide Rights to BiPhasix Transdermal Drug Delivery Technology
Altum Pharmaceuticals Inc., worldwide rights to BiPhasix Transdermal Drug Delivery technology comprises drug delivery technology rights. The asset is located in Canada. As of September 15, 2017, Altum Pharmaceuticals Inc., Worldwide Rights to BiPhasix Transdermal Drug Delivery Technology is merged into Pivot Pharmaceuticals Inc.

United States and Canada
Biotechnology
-
-
-
Pivot Pharmaceuticals Manufacturing Corp.
Pivot Pharmaceuticals Manufacturing Corp. was incorporated in 2019 and is based in Toronto, Canada. Pivot Pharmaceuticals Manufacturing Corp. operates as a subsidiary of BetterLife Pharma Inc.

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-31-2023
Aug-31-2023
Private Placement
Target
BetterLife Pharma Inc. (OTCPK:BETR.F)


0.22
Jul-13-2023
Jul-13-2023
Private Placement
Target
BetterLife Pharma Inc. (OTCPK:BETR.F)


0.17
Mar-14-2023
Mar-14-2023
Private Placement
Target
BetterLife Pharma Inc. (OTCPK:BETR.F)


0.26
Mar-07-2023
Mar-14-2023
Private Placement
Target
BetterLife Pharma Inc. (OTCPK:BETR.F)


0.11
Dec-07-2022
Dec-07-2022
Private Placement
Target
BetterLife Pharma Inc. (OTCPK:BETR.F)
Negev Capital

0.47
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-18-2023
Special Calls
BetterLife Pharma Inc. - Special Call
Sep-12-2023
Product-Related Announcements
BetterLife Pharma Inc. Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
Aug-31-2023
Private Placements
BetterLife Pharma Inc. announced that it has received CAD 0.295 million in funding
Jul-13-2023
Private Placements
BetterLife Pharma Inc. announced that it has received CAD 0.22 million in funding
Jun-27-2023
Product-Related Announcements
BetterLife Pharma Inc. Fast Tracking Its US Patent for BETR-001 and Other LSD Derivatives

M&A Advisors
Alexander Holburn Beaudin & Lang LLP, Blake, Cassels & Graydon LLP, Fasken Martineau DuMoulin LLP, Origin Merchant Partners


Advisors
Most Recent Auditor
MNP LLP
M&A Advisors
Alexander Holburn Beaudin & Lang LLP, Blake, Cassels & Graydon LLP, Fasken Martineau DuMoulin LLP, Origin Merchant Partners
Private Placement Advisors
Bloom Burton Securities Inc., Fasken Martineau DuMoulin LLP, Haywood Securities Inc., Origin Merchant Partners, Research Capital Corporation
Public Offering Advisors
Alexander Holburn Beaudin & Lang LLP, MNP LLP


Most Recent Auditor
Meyers Norris Penny LLP - MNP LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

03:46 AM
BETR.F
BetterLife Pharma Inc 2023_10_05
Reports
14
GlobalData

Sep 15, 2023 12:23 AM
BETR.F
Better Life Pharmaceuticals Inc (BETR) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
70
GlobalData

Sep 13, 2023 01:57 AM
BETR.F
Better Life Pharmaceuticals Inc (BETR) - Financial Analysis Review
Reports
163
S&P Global Compustat

Sep 07, 2023 03:33 AM
BETR.F
BetterLife Pharma Inc 2023_09_07
Reports
14
GlobalData

Aug 23, 2023 06:33 AM
BETR.F
Better Life Pharmaceuticals Inc - Medical Equipment - Deals and Alliances Profile
Reports
26
GlobalData

Aug 18, 2023 04:46 AM
BETR.F
Better Life Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
53
S&P Global Compustat

Jul 06, 2023 03:15 AM
BETR.F
BetterLife Pharma Inc 2023_07_06
Reports
14
GlobalData

Jun 09, 2023 05:02 AM
BETR.F
Better Life Pharmaceuticals Inc (BETR) - Financial Analysis Review
Reports
183
GlobalData

Jun 09, 2023 04:53 AM
BETR.F
Better Life Pharmaceuticals Inc (BETR) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
88
S&P Global Compustat

Jun 01, 2023 03:57 AM
BETR.F
BetterLife Pharma Inc 2023_06_01
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Doroudian Ph.D., Ahmad 

9,164,967

8.05

0.7

Aug-31-2023


Sheshbaradaran Ph.D., Hooshmand 

1,386,281

1.22

0.1

May-29-2023


Ong C.A., CPA, CA, CFA, Moira 

637,825

0.56

0.0

May-29-2023


Renz M.D., Ph.D., Wolfgang 

36,500

0.03

0.0

May-29-2023


Metcalfe L.L.B., Robert James

30,000

0.03

0.0

May-29-2023


Bartlett & Co. LLC

4,000

0.00

0.0

Jun-30-2023


Pullen, Ralph Anthony

3,000

0.00

0.0

May-29-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Doroudian Ph.D., Ahmad 
9,164,967
1,000,000

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
2-Bromo-LSD (Future), AP-003 (Future), BETR-001 (Future), Bulk Powder (Future), Candies (Future), Capsules and Soft Gels (Future), Creams (Future), Dihydrohonokiol-B (Future), Gums (Future), Infused Beverages (Future), Intimate Lubricant (Future), Lotions (Future), Mints (Future), NK-001 (Future), NK-002 (Future), Oral Solutions (Future), Pet Supplements (Future), PGS-N001 (Future), PGS-N002 (Future), PGS-N003 (Future), PGS-N005 (Future), Stick Packs (Future), Tablets (Future)


Upcoming Events
Date/Time
Type
Dec-28-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-29-2023
Sep-29-2023
BetterLife Pharma Inc. (OTCPK:BETR.F)
SEC
6-K
60 KB
Sep-29-2023
-
BetterLife Pharma Inc. (OTCPK:BETR.F)
SEDAR
Material Change Report
208 KB
Sep-28-2023
Jul-31-2023
BetterLife Pharma Inc. (OTCPK:BETR.F)
SEC
6-K
759 KB
Sep-27-2023
Jul-31-2023
BetterLife Pharma Inc. (OTCPK:BETR.F)
SEDAR
Interim Financial Statements
425 KB
Sep-14-2023
-
BetterLife Pharma Inc. (OTCPK:BETR.F)
SEDAR
News Releases
22 KB
Sep-12-2023
-
BetterLife Pharma Inc. (OTCPK:BETR.F)
SEDAR
News Releases
21 KB
Sep-05-2023
Sep-05-2023
BetterLife Pharma Inc. (OTCPK:BETR.F)
SEC
6-K
38 KB
Sep-05-2023
-
BetterLife Pharma Inc. (OTCPK:BETR.F)
SEDAR
Material Change Report
225 KB
Sep-05-2023
-
BetterLife Pharma Inc. (OTCPK:BETR.F)
SEDAR
News Releases
24 KB
Jul-13-2023
Jul-13-2023
BetterLife Pharma Inc. (OTCPK:BETR.F)
SEC
6-K
40 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Doroudian Ph.D., Ahmad  (Founder, CEO & Chairman)
Aug-31-2023
Common Stock
1,000,000
0
Private Acquisition
12.25
Multiple
Doroudian Ph.D., Ahmad  (Founder, CEO & Chairman)
Mar-14-2023
Common Stock
2,000,000
200,872
Private Acquisition
36.32
Multiple
Doroudian Ph.D., Ahmad  (Founder, CEO & Chairman)
Mar-06-2023 - Apr-14-2023
Common Stock
658,600
70,383
Open Market Acquisition
8.77
Multiple
-
Mar-06-2023
Common Stock
265,500
32,941
Open Market Acquisition
-
Exchange Announcement
-
Mar-16-2023
Common Stock
148,000
14,783
Open Market Acquisition
-
Exchange Announcement
-
Apr-14-2023
Common Stock
245,100
22,658
Open Market Acquisition
-
Exchange Announcement
Doroudian Ph.D., Ahmad  (Founder, CEO & Chairman)
Feb-14-2023
Common Stock
329,500
54,197
Open Market Acquisition
6.36
Multiple
Doroudian, Hamid  (Former Chief Executive Officer, President, Secretary and Director)
Dec-30-2022
Common Stock
(303,950)
-
Private Disposition
(100.00)
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Doroudian, Ahmad 
Founder, CEO & Chairman
604-805-7783
604-738-7134
ahmad.doroudian@blifepharma.com
Aguilar-Valles, Argel 
Member of Scientific Advisory Board
613-520-2600 x7044
604-738-7134
Argel.AguilaValles@Carleton.ca
Halberstadt, Adam 
Member of Scientific Advisory Board
604-221-0595
604-738-7134

McCorvy, John D.
Member of Scientific Advisory Board
(414) 955-7635
(414) 955-6517
jmccorvy@mcw.edu
Metcalfe, Robert James
Independent Director
604-221-0595
604-738-7134

Pullen, Ralph Anthony
Independent Director
604-221-0595
604-738-7134

Renz, Wolfgang 
Independent Director
604-221-0595
604-738-7134

Swaim, Mark 
Member of Advisory Board
604-221-0595
604-738-7134

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Doroudian, Ahmad 
Founder, CEO & Chairman
604-805-7783
604-738-7134
ahmad.doroudian@blifepharma.com
Ong, Moira 
Chief Financial Officer
604-221-0595
604-738-7134

Sheshbaradaran, Hooshmand 
Chief Operating Officer
604-221-0595
604-738-7134

Calandra, Anthony 
Head of Regulatory
604-221-0595
604-738-7134

Ghaffari, Abdi 
Head of Preclinical & Toxicology
604-221-0595
604-738-7134

Rudge, Scott 
Head of CMC
604-221-0595
604-738-7134

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
